Elevation Oncology, Inc.
Elevation Oncology, Inc. (ELEV): 5 pipeline candidates · ~19 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
18.9 months
D/E 0.76 · 0% dilution
Lead: Phase 2
5 candidates
N/A
N/A
A transparent, data-derived signal for Elevation Oncology, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$60.5M
Quarterly Burn
$12.7M
Runway
18.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| EO-1022 | Preclinical |
| EO-3021 | Phase 1 |
| EO-3021 (also known as SYSA1801 or CPO102) | Phase 1 |
| HER3-ADC (unnominated) | Preclinical |
| seribantumab | Phase 2 |
Frequently asked questions
How many drug candidates are in Elevation Oncology, Inc.'s pipeline?
Elevation Oncology, Inc. (ELEV) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Elevation Oncology, Inc.'s lead drug candidate?
Elevation Oncology, Inc.'s most advanced tracked candidate is EO-1022 (Preclinical) for Treatment of patients with HER3-expressing solid tumors, including breast cancer and non-small cell lung cancer (and other solid tumors).
What is Elevation Oncology, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Elevation Oncology, Inc. has approximately 18.9 months of cash runway.
Who is the CEO of Elevation Oncology, Inc.?
Chief Executive Officer is the chief executive officer of Elevation Oncology, Inc. (ELEV).
Get the full picture on Elevation Oncology, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.